A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737
This study is recruiting at 51 US sites in 25 states, according to its ClinicalTrials.gov record last updated .
Summary
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer
- Prostatic Neoplasms
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Mayo Clinic in Arizona - Phoenix ( Site 0044) · Phoenix, AZ
California · 9
- Community Cancer Institute ( Site 0081) · Clovis, CA
- City of Hope Comprehensive Cancer Center ( Site 0049) · Duarte, CA
- City of Hope Lennar Foundation Cancer Center ( Site 0059) · Irvine, CA
- Moores Cancer Center ( Site 0010) · La Jolla, CA
- Veterans Affairs Long Beach Healthcare System ( Site 0058) · Long Beach, CA
- Cedars-Sinai Medical Center ( Site 0068) · Los Angeles, CA
- UCLA Hematology/Oncology - Santa Monica ( Site 0002) · Los Angeles, CA
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0006) · Orange, CA
- Stanford Cancer Center ( Site 0046) · Palo Alto, CA
Colorado · 1
- Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0053) · Aurora, CO
Connecticut · 2
- Yale-New Haven Hospital-Yale Cancer Center ( Site 0050) · New Haven, CT
- Veterans Affairs Connecticut Healthcare System ( Site 0062) · West Haven, CT
District of Columbia · 1
- Washington DC Veterans Affairs Medical Center ( Site 0056) · Washington D.C., DC
Florida · 3
- Clermont Oncology Center ( Site 0087) · Clermont, FL
- Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0077) · Jacksonville, FL
- Mid Florida Hematology and Oncology Center ( Site 0086) · Orange City, FL
Georgia · 2
- Emory University School of Medicine- Grady Campus ( Site 0103) · Atlanta, GA
- Winship Cancer Institute, Emory University ( Site 0003) · Atlanta, GA
Illinois · 2
- Rush University Medical Center-Hematology and Oncology ( Site 0028) · Chicago, IL
- University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063) · Chicago, IL
Kentucky · 1
- University of Kentucky Chandler Medical Center ( Site 0048) · Lexington, KY
Maryland · 1
- Greenebaum Comprehensive Cancer Center ( Site 0021) · Baltimore, MD
Massachusetts · 2
- Beth Israel Deaconess Medical Center ( Site 0043) · Boston, MA
- Dana Farber Cancer Institute ( Site 0012) · Boston, MA
Michigan · 3
- University of Michigan ( Site 0005) · Ann Arbor, MI
- Henry Ford Hospital ( Site 0035) · Detroit, MI
- Cancer and Hematology Centers of Western Michigan ( Site 0015) · Grand Rapids, MI
Minnesota · 3
- Mayo Clinic in Rochester, Minnesota-Mayo Clinic Comprehensive Cancer Center ( Site 0078) · Rochester, MN
- HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0032) · Saint Louis Park, MN
- HealthPartners Cancer Center at Regions Hospital ( Site 0052) · Saint Paul, MN
Montana · 1
- St. Vincent Frontier Cancer Center-Research ( Site 0037) · Billings, MT
Nevada · 1
- Comprehensive Cancer Centers of Nevada ( Site 0082) · Las Vegas, NV
New Jersey · 1
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016) · Hackensack, NJ
New Mexico · 1
- University of New Mexico Comprehensive Cancer Center ( Site 0022) · Albuquerque, NM
New York · 2
- Icahn School of Medicine at Mount Sinai ( Site 0009) · New York, NY
- Great Lakes Cancer Care ( Site 0047) · Williamsville, NY
Ohio · 1
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0061) · Columbus, OH
Oregon · 1
- VA Portland Health Care System ( Site 0038) · Portland, OR
Pennsylvania · 2
- Abramson Cancer Center - Penn Medicine ( Site 0079) · Philadelphia, PA
- Perelman Center for Advanced Medicine ( Site 0067) · Philadelphia, PA
Tennessee · 3
- Memphis VA Medical Center ( Site 0072) · Memphis, TN
- Henry-Joyce Cancer Clinic ( Site 0042) · Nashville, TN
- SCRI Oncology Partners ( Site 0074) · Nashville, TN
Texas · 3
- Parkland Health & Hospital System ( Site 0069) · Dallas, TX
- UT Southwestern Medical Center ( Site 0039) · Dallas, TX
- University of Texas-MD Anderson Cancer Center ( Site 0055) · Houston, TX
Washington · 2
- Fred Hutchinson Cancer Center ( Site 0060) · Seattle, WA
- VA Puget Sound Health Care System ( Site 0054) · Seattle, WA
Wisconsin · 2
- University Hospital and UW Health Clinics ( Site 0065) · Madison, WI
- Medical College of Wisconsin ( Site 0008) · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.